Vedolizumab in combined immune checkpoint therapy-induced infliximab-refractory colitis in a patient with metastatic melanoma: A case report

doi:10.5306/wjco.v10.i10.350

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 10

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5689)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series.

Item

Count

PDF

652

WORD

196

HTML

2968

Figures (1-3)

248

Sum=4064

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

689

Download

936

Sum=1625

Oct 24, 2019 (publication date) through Nov 14, 2024

Times Cited of This Article

Times Cited (12)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Clin Oncol. Oct 24, 2019; 10(10): 350-357
Published online Oct 24, 2019. doi: 10.5306/wjco.v10.i10.350

Full Size Figure Download Figure

Figure 1 High power (200 ×) haematoxylin and eosin stained section showing neutrophilic crypt abscesses, no viral inclusion bodies seen.

Citation: Randhawa M, Gaughran G, Archer C, Pavli P, Morey A, Ali S, Yip D. Vedolizumab in combined immune checkpoint therapy-induced infliximab-refractory colitis in a patient with metastatic melanoma: A case report. World J Clin Oncol 2019; 10(10): 350-357
URL: https://www.wjgnet.com/2218-4333/full/v10/i10/350.htm
DOI: https://dx.doi.org/10.5306/wjco.v10.i10.350